The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.

Eisai/Biogen could this week learn whether the European Medicines Agency will give the thumbs up to market lecanemab across the EU for early Alzheimer’s disease.

Iqirvo gains accelerated approval, but Gilead’s seladelpar is probably only two months behind.

The France-based mid-sized drugmaker has solidified its pipeline through several external pacts in the past few years and its dealmaking is showing no signs of slowing down.